This episode is brought to you by Focus Features.
On March 27th, Focus Features invites you
to be a part of the most explosive movie of this year's Sundance and South by Southwest Film Festivals.
The AI Doc or How I Became an Apocalypse is being called supremely entertaining
and the most urgent movie of our time.
The AI Doc or How I Became an Apocalypse rated PG-13 only in theaters March 27th.
For Scientific American Science Quickly, I'm Kendra Peer-Lewis in for Rachel Feldman.
In early March, the U.S.
Food and Drug Administration sent a warning letter to Novo Nordisk, the maker of Ozympic and Mugovie,
saying the company had failed to disclose potential risks associated with taking these drugs.
The agency alleged that Novo Nordisk failed a proper report and or follow-up on three deaths of individuals
who were taking somaglotide, the key ingredient in Ozympica mogovii.
The drugs are part of a broader class of medicine, known as GLP-1s,
that have grown wildly popular for everything from type 2 diabetes to weight loss and are increasingly seen
as having potential benefits far beyond those two conditions.
The popularity of these drugs has led to a sea of GLP-1 offerings flooding the market.
Not all of them FDA approved.
We sat down with Lauren Young, an associate editor covering health and medicine for Scientific American,
to talk about where GLP-1s go from here.
Thank you for being here, Lauren.